Table 2.

Studies describing urinary tract involvement

Studies [Ref.]	Pre‐existing urological conditions type (no./totala)	Time from exposure/diagnosis to onset of symptoms (days) mean (range)	Signs/symptoms type (no./totala)	Symptom score	Laboratory findings		Management
					Urinalysis pathologic finding type no./totalb	Urine culture findings type no./totalb
Lamb et al.  26	n/a	n/a	De novo urgency (4/4) De novo urge incontinence (4/4) De novo frequency (4/4) De novo nocturia (4/4)	n/a	n/a	n/a	n/a
Mumm et al. 15	BPH (1/7)	n/a	Increased urinary frequency (7/7)	n/a	Microhematuria (3/7) Leukocyturia (2/4)	Negative (6/6)	n/a
Luciani et al. 27	Radiation cystitis (1/3) BPH (2/3)	6.3 (5‐8)	Hematuria (3/3) Urinary retention (1/3)	n/a	n/a	n/a	Endoscopy (1/3) Embolization (1/3) Conservative (1/3)
Dhar et al. 28	n/a	n/a	De novo urgency (39/39) De novo urge incontinence (39/39) De novo frequency (39/39) De novo nicturia (39/39)	Men: 18 (12–20)c, d Women: 18 (15–21)c, d	n/a	Negative (39/39)	n/a
Kaya et al. 29	n/a	n/a	n/a	IPSS total Pre‐COVID‐19: 6.1 (7.3)e During hospitalization: 6.2 (7.5)e Post hospitalization: 5.7 (7.2)e (p : .148) IPSS storage Pre‐COVID‐19: 3.2 (4.1)e During hospitalization: 3.2 (4.3)e Post hospitalization: 2.8 (4)e (p : .054) IPSS voiding Pre‐COVID‐19: 2.9 (3.5)e During hospitalization: 3.1 (3.5)e Post hospitalization: 2.9 (3.4)e (p : .933)	n/a	n/a	n/a
Kaya et al. 29	n/a	n/a	n/a	USP Scale (stress urinary incontinence) Pre‐COVID‐19: 0.5 (1.9)e During hospitalization: 0.7 (1.9)e Post hospitalization: 0.5 (1.9)e (p : .05) USP Scale (overactive bladder) Pre‐COVID‐19: 2.2 (2.9)e During hospitalization: 2.3 (3)e Post hospitalization: 1.9 (2.6)e (p : .051) USP Scale (slow current) Pre‐COVID‐19: 0.1 (0.4)e During hospitalization: 0 (0)e Post hospitalization: 0 (0)e (p : .368)	n/a	n/a	n/a

Abbreviations: BPH, benign prostate hyperplasia; IPSS, International Prostate Symptom Score; USP, urinary symptom profile.

^a Total patients with signs and/or symptoms and/or laboratory findings of urinary tract involvement.

^b Total patients for whom the laboratory evaluation was available.

^c Overactive Bladder symptom score.

^d Median (range).

^e Mean (standard deviation).